Chronic lymphocytic leukaemia: open trials in Japan

13 open trials have a site in Japan. Registry data; only the trial team decides who can take part.

NCT05947851
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital (Site 3006), Hiroshima · Shimane University Hospital (Site 3009), Izumo · Cancer Institute Hospital of JFCR (Site 3003), Koto · Nagasaki University Hospital (Site 3008), Nagasaki · Kochi Medical School Hospital (Site 3007), Nankoku · National Hospital Organization Osaka National Hospital (Site 3004), Osaka · Kindai University Hospital (Site 3005), Sakai · Hokkaido University Hospital (Site 3000), Sapporo · Yamagata University Hospital (Site 3002), Yamagata
Registry updated 2026-11-06
NCT06788509
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Trial Treatment · Phase 1 · Janssen Research & Development, LLC
National Hospital Organization Nagoya Medical Center, Nagoya · The Cancer Institute Hospital of JFCR, Tokyo
Registry updated 2026-11-04
NCT07218341
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Trial Treatment · Phase 4 · Eli Lilly and Company
Tokai University Hospital, Isehara
Registry updated 2026-11-04
NCT06564038
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Trial Treatment · Phase 1/2 · AstraZeneca
Kōtoku · Matsuyama · Nagoya
Registry updated 2026-10-28
NCT06136559
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Chiba Cancer Center (Site 1905), Chiba · Kyushu University Hospital (Site 1914), Fukuoka · Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital (Site 1913), Hiroshima · Shimane University Hospital (Site 1911), Izumo · Kobe City Medical Center General Hospital (Site 1910), Kobe · Cancer Institute Hospital of JFCR (Site 1906), Koto · Gunma University Hospital (Site 1903), Maebashi · Nagoya University Hospital (Site 1907), Nagoya · Okayama University Hospital (Site 1912), Okayama · Japanese Red Cross Osaka Hospital (Site 1908), Osaka · Kindai University Hospital (Site 1909), Sakai · Hokkaido University Hospital (Site 1900), Sapporo · Tohoku University Hospital (Site 1901), Sendai · Yamagata University Hospital (Site 1902), Yamagata
Registry updated 2026-10-13
NCT05006716
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Trial Treatment · Phase 1/2 · BeOne Medicines
Chiba Cancer Center, Chiba · National Cancer Center Hospital East, Kashiwa · Cancer Institute Hospital of JFCR, Kōtoku · Aichi Cancer Center Hospital Clinical Oncology, Nagoya · Yokohama Municipal Citizens Hospital, Yokohama
Registry updated 2026-10-05
NCT06542250
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Trial Treatment · Phase 1/2 · AstraZeneca
Chūōku · Kashiwa
Registry updated 2026-09-30
NCT06846671
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Trial Treatment · Phase 3 · BeOne Medicines
Hyogo Prefectural Amagasaki General Medical Center, AmagasakiCity · Tokyo Metropolitan Komagome Hospital, Bunkyoku · Chiba Cancer Center, Chiba · Kansai Medical University Hospital, Hirakata · Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital, Hiroshima · Kagoshima University Hospital, Kagoshima · Saitama Medical Center, Kawagoeshi · Kumamoto University Hospital, Kumamoto · Kurashiki Central Hospital, Kurashikishi · University Hospital, Kyoto Prefectural Univ of Medicine, KyotoShi · NHO Shikoku Cancer Center, Matsuyama · Aichi Cancer Center Hospital Clinical Oncology, Nagoya · Niigata University Medical and Dental Hospital, Niigata · National Hospital Organization Okayama Medical Center, Okayama · Osaka Metropolitan University Hospital, Osaka · Kindai University Hospital, Sakai · Aiiku Hospital, Sapporo · Tohoku University Hospital, Sendai · Ntt Medical Center Tokyo, Shinagawaku
Registry updated 2026-09-28
NCT06973187
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Trial Treatment · Phase 3 · BeOne Medicines
Tokyo Metropolitan Komagome Hospital, Bunkyoku · Fukushima Medical University Hospital, Fukushima · Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital, Hiroshima · Dokkyo Medical University Saitama Medical Center, Koshigaya · Cancer Institute Hospital of JFCR, Kōtoku · Kumamoto University Hospital, Kumamoto · Japanese Red Cross Kyoto Daini Hospital, Kyotoshi · Matsuyama Red Cross Hospital, Matsuyama · Aichi Cancer Center Hospital Clinical Oncology, Nagoya · Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nakamuraku · Kochi Medical School Hospital, Nankoku · Oita Prefectural Hospital, Ōita · Okayama University Hospital, Okayama · Osaka Metropolitan University Hospital, Osaka · Kindai University Hospital, Sakai · Aiiku Hospital, Sapporo · National Hospital Organization (Nho) Disaster Medical Center, Tachikawashi · Yamagata University Hospital, Yamagata
Registry updated 2026-09-28
NCT05254743
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Trial Treatment · Phase 3 · Loxo Oncology, Inc.
Kumamoto University Hospital, Kumamoto · Yamagata University Hospital, Yamagata
Registry updated 2026-08-17
NCT06876649
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Trial Treatment · Phase 4 · Eli Lilly and Company
Nagoya Medical Center, Aichi-Ken · National Cancer Center Hospital, Cho-ku · National Hospital Organization Kyushu Cancer Center, Fukuoka · Tokai University Hospital- Isehara Campus, Isehara · Tohoku University Hospital, Miyagi-Ken · Hokkaido University Hospital, Sapporo
Registry updated 2026-03-02
NCT06876662
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Trial Treatment · Phase 4 · Eli Lilly and Company
Nagoya Medical Center, Aichi-Ken · National Cancer Center Hospital, Cho-ku · National Hospital Organization Kyushu Cancer Center, Fukuoka · Tokai University Hospital- Isehara Campus, Isehara · Tohoku University Hospital, Miyagi-Ken · Hokkaido University Hospital, Sapporo
Registry updated 2026-03-02
NCT06357754
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Research · Bristol-Myers Squibb
Kumamoto · Toyokawa City Hospital, Toyokawa
Registry updated 2026-01-22

All Chronic lymphocytic leukaemia trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error